LATE-BREAKING ABSTRACT SUBMISSION GUIDELINES
The Late-Breaking Abstract Submission site opens January 2, 2020 and closes February 14, 2020 @11:59 PM EST

AUA’s late-breaking abstract policy allows the submission of late-breaking abstracts only for trials for which no preliminary data are available at the time of the abstract submission deadline (November 1, 2019).

The policy is not a mechanism to allow updated data to be submitted late when preliminary data were available by the abstract submission deadline or to provide an opportunity to revise previously rejected abstracts and resubmit for consideration. Case Reports are unacceptable. Preliminary results for Trials in Progress must be submitted.

Newsworthy trials for which the author(s) is compelled (embargoed) not to publish the results (even in abstract form) may be submitted without primary end-point results or written final conclusions. The Secretary will work on a one-on-one basis to confirm that sufficient information is included in the abstract for consideration.

Late-breaking abstracts may be presented on the Plenary Program. Therefore, authors are required to confirm that their work has not been previously presented or published elsewhere as an abstract or manuscript.

Preparation of Abstracts: Follow steps 1 to 9 above.

These abstracts are intended to allow for the timely presentation of late-breaking news of interest to annual meeting attendees. Priority will be given (in the following order) to:

• Results of phase III clinical trials
• Results of phase II clinical trials
• Interim analyses of phase III trials that describe important secondary end points
• Prospective multi-institution clinical trials

The authors must fully describe all funding sources for their investigation.

Preparation of Abstracts
1. Size: The size of the abstract is limited to 2,280 characters not including spaces. This includes title, body of abstract, tables and graphics. Tables are calculated at 225 characters per table. Graphics are calculated at 225 characters per graphic.

2. Title: The title should clearly define the topic and contain no abbreviations.

3. Authors: List the primary author’s full name, followed by the other authors’ names. Spell out completely the names of all authors using full first name, middle initial and last name. (Maintain consistency in authors’ names on multiple abstracts to avoid duplication in the Author Index.)

4. Presenting Author: If the author(s) of the abstract is an employee(s) of or has a financial relationship with the commercial interest which controls the content of the
presentation then he/she cannot be the presenting author. However, principal investigators responsible for research and development are permitted to present as long as they resolve their COI and as long as they are not employees of the commercial interest. In all printed publications the presenting author will be denoted with an asterisk (*). Please note: As of February 3, 2020 no changes to the Presenting Author will be made in the Program Abstract Publication.

5. Body of Abstract: The abstract should be informative and detailed.

- The body must contain 4 separate paragraphs: a) Introduction and Objective, b) Methods, c) Results and d) Conclusions.
- It is NOT acceptable to state that "The results will be discussed." Inclusion of specific outcomes data is necessary for all abstracts; this applies to Trials in Progress as well.
- Indicate the major new findings of the study.
- Standard abbreviations may be used as follows: on first use spell out the full term and follow with the abbreviation in parentheses.
- Graphs and/or tables may be used; characters in graphs and tables are counted towards the overall character limit of the abstract.
- Proprietary names of drugs are not allowed; generic names must be used.

6. Source of Funding: Grant support must be indicated on the "Source of Funding" page. If there is no support, "None" must be listed. This is a required field in the submission process. Abstracts deemed to be purely for marketing purposes will not be accepted.

7. Conflict of Interest and Disclosure Statement: All authors must disclose conflicts of interest. The electronic submission process will not allow abstracts to be submitted without this information being completed for each author listed on the abstract.

8. Category List: Authors must select a category (only one) from the provided list.

9. Keywords: Authors must select up to 3 keyword entries from the provided Keyword Index that best describes the subject of the abstract.